Michael Gentile, MD
Internal Medicine · Nutley, NJNPI 1982675773
Payments from drug & device makers
Across 117 payments — averaging $258.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- AstraZeneca$507
- Amarin Pharma, Inc.$483
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$456
- Boehringer Ingelheim$267
- GSK$142
- plus $281 from 9 others
What the payments were for
- Speaking & faculty fees$25,62585%
- Travel & lodging$1,1524%
- Food & beverage$3,49012%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $28,137 |
| AstraZeneca | 7 | $507 |
| Amarin Pharma, Inc. | 11 | $483 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $456 |
| Boehringer Ingelheim | 4 | $267 |
| GSK | 4 | $142 |
| Supernus Pharmaceuticals, Inc. | 4 | $122 |
| Exact Sciences | 2 | $37 |
| Gilead | 2 | $25 |
| Boston Scientific | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,273 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $7,817 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $7,223 |
| Spiriva HandihalerTiotropium Bromide | 11 | $5,669 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,825 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 71 | $1,334 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $988 |
| Metoprolol Succinate | 45 | $857 |
| Omeprazole | 40 | $622 |
| Atorvastatin Calcium | 51 | $599 |
| Ezetimibe | 26 | $585 |
| Tamsulosin Hcl | 24 | $584 |
| Levothyroxine Sodium | 41 | $455 |
| Losartan Potassium | 31 | $447 |
| Amlodipine Besylate | 51 | $436 |
| Famotidine | 28 | $424 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Nutley
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.